Cargando…
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin
Cisplatin resistance has been a major factor limiting its clinical use as a chemotherapy drug. The present study aimed to investigate whether SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase closely associated with tumors can affect the sensitivity of tumors to cisplatin...
Autores principales: | Wang, Lei, Xu, Man-Li, Wang, Chang, Dong, Qing-Qing, Miao, Zhi, Chen, Xiao-Ying, Wang, Nan, He, Hong-Peng, Zhang, Tong-Cun, Luo, Xue-Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114722/ https://www.ncbi.nlm.nih.gov/pubmed/32269620 http://dx.doi.org/10.3892/ol.2020.11465 |
Ejemplares similares
-
Structure and Function of SET and MYND Domain-Containing Proteins
por: Spellmon, Nicholas, et al.
Publicado: (2015) -
Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer
por: Alshammari, Eid, et al.
Publicado: (2022) -
SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer
por: Liu, Ting-Ting, et al.
Publicado: (2016) -
Structural and Functional Analysis of the DEAF-1 and BS69 MYND Domains
por: Kateb, Fatiha, et al.
Publicado: (2013) -
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma
por: Xu, Wenchao, et al.
Publicado: (2018)